| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H14N2O6S |
| Molecular Weight | 374.368 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)NC1=CC2=C(C=C1OC3=CC=CC=C3)C(=O)C(NC=O)=CO2
InChI
InChIKey=ANMATWQYLIFGOK-UHFFFAOYSA-N
InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)
| Molecular Formula | C17H14N2O6S |
| Molecular Weight | 374.368 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iguratimod, a methanesulfonanilide, is an anti-inflammatory drug for the treatment of rheumatoid arthritis that has been developed exclusively in Japan and China. It inhibits the production of immunoglobulins and various inflammatory cytokines (interleukin-1, -6 and -8 and TNF), and exerts anabolic effects on bone metabolism by stimulating osteoblastic differentiation and inhibiting osteoclastogenesis. On the molecular level, it inhibits the nuclear transcription factor NF-κB but not its inhibitor, IκBα. In addition to these immunomodulatory and other long-lasting effects, iguratimod inhibits cyclooxygenase-2, which provides a synergistic short-term action against pain and inflammation. Efficacy and tolerability are comparable to salazosulfapyridine, and probably also to methotrexate. Combination with methotrexate is synergistic in patients with insufficient response to methotrexate and does not significantly increase adverse events.
Originator
Approval Year
Cmax
AUC
Doses
AEs
PubMed
Patents
Sample Use Guides
The usual adult dosage for oral use is 25 mg of iguratimod
once daily after breakfast for 4 weeks or more, after which
the dosage should be increased to one 25 mg tablet taken
twice daily (after breakfast and after supper).
Route of Administration:
Oral
